Cessation of Anti‐ <scp>VEGF</scp> Treatment Therapy in Age‐Related Macular Degeneration: A Narrative Review
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy has revolutionised the treatment of neovascular age-related macular degeneration (nAMD), significantly improving visual outcomes and enhancing the quality of life for affected patients. However, the decision to discontinue anti-VEGF therapy in nAMD management remains complex and lacks consensus, with various criteria being applied. This narrative review examines the available evidence on the cessation of anti-VEGF treatment in nAMD in detail.
Authors
- Andreas Ebneter (ORCID: https://orcid.org/0000-0001-6666-2558)
- WengOnn Chan
- Bobak Bahrami (ORCID: https://orcid.org/0000-0003-1057-5142)
- Eiman Usmani (ORCID: https://orcid.org/0000-0001-7600-1526)
Institutions
- University of Bern (CH)
- Flinders Medical Centre (AU)
- Queen Elizabeth Hospital (AU)
- The University of Adelaide (AU)
Publication Details
- Journal
- Clinical and Experimental Ophthalmology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1111/ceo.70034
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00